Sangivamycin

• CAT Number: M079668
• CAS Number: 18417-89-5
• Molecular Formula: C12H15N5O5
• Molecular Weight: 309.28
• Purity: ≥95%
• Synonyms: 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
• InChI: InChI=1S/C12H15N5O5/c13-9-6-4(10(14)21)1-17(11(6)16-3-15-9)12-8(20)7(19)5(2-18)22-12/h1,3,5,7-8,12,18-20H,2H2,(H2,14,21)(H2,13,15,16)/t5-,7-,8-,12-/m1/s1
• InChIKey: OBZJZDHRXBKKTJ-JTFADIMSSA-N
• SMILES: C1=C(C2=C(N=CN=C2N1C3C(C(C(O3)CO)O)O)N)C(=O)N

Sangivamycin (Cat No.: M079668) is a natural nucleoside analog antibiotic of the streptothricin family with notable antiviral, antitumor, and protein kinase inhibitory properties. It interferes with nucleic acid and protein synthesis by incorporating into RNA and disrupting cellular processes. Sangivamycin has demonstrated activity against various viruses, including poxviruses and retroviruses, and shows anticancer potential through inhibition of protein kinase C (PKC). Although not advanced as a clinical drug, it remains a valuable research tool for exploring cancer biology, virology, and kinase signaling pathways.

Reference

[1]. Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263(4):1682-1692.
[Content Brief]

[2]. Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282(20):15271-15283.
[Content Brief]